Space Research is emerging as a potential new avenue for India’s pharmaceutical industry, as scientists explore microgravity experiments to develop medicines. The country hopes to combine its established pharmaceutical capabilities with growing expertise in space technology.
India supplies affordable medicines and vaccines to international markets, earning recognition as the “pharmacy of the world.” Now, scientists, biotechnology companies and startups are examining how space-based laboratories could support pharmaceutical innovation.
The subject featured prominently at the Bengaluru Tech Summit, which concluded on November 19. During the event, researchers and space technology entrepreneurs discussed opportunities involving India’s proposed Bharatiya Antariksh Station.
The planned orbital facility could eventually provide scientists with a laboratory for biotechnology experiments. In particular, researchers are interested in microgravity, the near-weightless environment that exists in space.
On Earth, gravity can influence how protein crystals form and develop during scientific experiments. However, microgravity may allow certain crystals to grow more uniformly, giving researchers clearer opportunities to examine molecular structures.
This difference could help scientists understand proteins in greater detail and explore improved drug formulations. Consequently, pharmaceutical researchers see potential applications for microgravity in developing medicines and advancing biotechnology.
Biocon Executive Chairperson Kiran Mazumdar-Shaw highlighted the opportunities that space technology could create for the pharmaceutical sector. She said researchers could use these environments to modify molecular structures, develop new molecules and create intellectual property.
Meanwhile, the planned Indian space station forms part of a wider international shift towards commercial orbital research. With the International Space Station expected to retire around 2030, governments and private companies are exploring alternative facilities.
India intends to participate in this emerging field through its Bharatiya Antariksh Station programme. The proposed station is expected to become fully operational by 2035, offering future opportunities for scientific collaboration.
During a dedicated space biotechnology symposium, participants discussed the possibility of turning the facility into an international research hub. Such a role could connect Indian scientists with global researchers and biotechnology organisations.
However, scientists do not need to wait until the proposed station begins operating. Former Indian Space Research Organisation Chairman A.S. Kiran Kumar said researchers could already explore alternative platforms.
He identified ground-based facilities and parabolic flights as possible ways to conduct short-duration microgravity experiments. These methods could help scientists test research ideas before moving experiments into orbital environments.
Such early experiments could also help researchers understand which pharmaceutical investigations benefit most from reduced gravity. In turn, the findings could guide future research priorities aboard India’s planned space station.
India’s ambitions therefore extend beyond conventional space exploration and satellite technology. The country is also examining how its space programme could contribute to scientific research and pharmaceutical development.
As these discussions continue, Space Research could become an important part of India’s efforts to strengthen its biotechnology capabilities. The proposed orbital station represents a longer-term opportunity to connect space infrastructure with medical innovation.

